Drug Trial Radar · NCT02916056
2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)
Last checked: Nov 19, 2026Latest source record: Jun 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
297
Actual
Start
Dec 2016
Primary completion
Jun 1, 2018
Study completion Jun 1, 2018
Sponsor
- Lead sponsor
- vTv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Sep 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension study in patients with mild Alzheimer's disease who have completed participation in the azeliragon Phase 3 (STEADFAST) trial. Patients will receive azeliragon 5 mg/day for up to 2 years.
Conditions
- Alzheimer's Disease
Interventions
Azeliragon 5mgDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Subjects With at Least One Treatment-Emergent Adverse EventTime frame: up to 18 months
Locations
71 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Phoenix, Arizona
Site not named
Tucson, Arizona
Site not named
Bellflower, California
Site not named
Costa Mesa, California
Site not named
Fullerton, California
Site not named
Glendale, California
Site not named
Imperial, California
Site not named
Irvine, California
Site not named
Laguna Hills, California
Site not named
Long Beach, California
Site not named
Riverside, California
Site not named
San Bernardino, California
Site not named
Santa Ana, California
Site not named
Atlantis, Florida
Site not named
Delray Beach, Florida
Site not named
Hallandale, Florida
Site not named
Hialeah, Florida
Site not named
Jacksonville, Florida
Site not named
Lake Worth, Florida
Site not named
Miami, Florida
Site not named
Miami, Florida
Site not named
Miami Beach, Florida
Site not named
Miami Lakes, Florida
Site not named
Orlando, Florida
Site not named
Sarasota, Florida
Site not named
Sunrise, Florida
Site not named
The Villages, Florida
Site not named
Columbus, Georgia
Site not named
Chicago, Illinois
Site not named
Fairway, Kansas
Site not named
Lexington, Kentucky
Site not named
Baltimore, Maryland
Site not named
Newton, Massachusetts
Site not named
Plymouth, Massachusetts
Site not named
Quincy, Massachusetts
Site not named
Hattiesburg, Mississippi
Site not named
Creve Coeur, Missouri
Site not named
St Louis, Missouri
Site not named
Princeton, New Jersey
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.